As of Oct 21
| -0.01 / -0.14%|
The 6 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 10.50, with a high estimate of 14.00 and a low estimate of 7.00. The median estimate represents a +48.73% increase from the last price of 7.06.
The current consensus among 7 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.